CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%

CV Sciences, Inc.

2022-Q2 EPS reported -$0.05 revenue$8,585,000

Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.
Gross margin 30.7% vs 44.7% in Q2 2021, hurt by product mix and higher discounts.
Operating loss narrowed to $2.3M from $3.5M; adj. EBITDA loss $1.8M (vs $2.4M).
Cash balance $1.1M at quarter end; OPEX reduced 38.2% YoY.
Regained top hemp extract brand in natural retail per SPINS; strategic review ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.